Ivosidenib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 76 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page12 sections

Article Summary

Ivosidenib is an orally available small-molecule inhibitor of isocitrate dehydrogenase 2 which is used as an antineoplastic agent in the treatment of selected cases of acute myeloid leukemia (AML). Ivosidenib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to be the cause of rare instances of clinically apparent acute liver injury. Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Reading text size
Definition

Ivosidenib is an orally available small-molecule inhibitor of isocitrate dehydrogenase 2 which is used as an antineoplastic agent in the treatment of selected cases of myeloid (AML). Ivosidenib is associated with a rate of serum aminotransferase elevations during therapy and is suspected to be the cause of rare instances of clinically apparent acute injury.

Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.

Ivosidenib is a tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. It has a role as an antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is a member of monochlorobenzenes, a cyanopyridine, a member of pyrrolidin-2-ones, an organofluorine compound, a tertiary carboxamide, and a secondary carboxamide.

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma.[rx] It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to the differentiation of cells.[rx]

Ivosidenib was approved for medical use in the United States in July 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[rx]

Mechanism of Action

Ivosidenib is a reversible inhibitor of IDH1 which is non-competitive with respect to the cofactor NADH. It binds to many different 132-substituted IDH1 mutants as well as the wild-type enzyme. It is considered to be a slow-binder of the wild-type enzyme and binds to mutant enzymes at lower concentrations, both of which may contribute to its selectivity. Ivosidenib has not been observed to inhibit any form of IDH2 at micromolar concentrations.

Many cancers undergo missense mutations of their IDH1 gene leading to the substitution of arginine 132 residues of the IDH1 enzyme [A35629. This substitution leads to reduced production of the normal carboxylic acid cycle metabolite α-ketoglutarate (α-KG) in favor of a new metabolite, D-2-hydroxyglutarate (D-2HG) which reaches levels of 50-100 fold that of wild type cells. D-2HG is a weak competitor to α-KG, inhibiting aKG-dependent dioxygenases, and is present. These dioxygenases include several histone demethylases. This leads to hypermethylation of histones, a dominant feature of AML, which is associated with less expression of cell-differentiation genes. Furthermore, methylation-sensitive insulators can no longer regulate the activation of oncogenes when histones are hypermethylated. In AML this hypermethylation is known to disrupt hematopoietic differentiation. Ivosidenib reduces the production of D-2HG, relieving the inhibition of histone demethylases and restoring normal methylation conditions. This restores cell differentiation and regulation leading to the regression of cancer.

Indications

  • Ivosidenib is an orally available small-molecule inhibitor of isocitrate dehydrogenase 2 which is used as an antineoplastic agent in the treatment of selected cases of acute myeloid leukemia (AML).
  • Ivosidenib is approved for use in the treatment of relapsed or AML with a susceptible IDH1 mutation as detected by an FDA-approved test.
  • Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumors, hematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of the central nervous system
  • Treatment of acute myeloid leukemia. Locally Advanced or Metastatic Cholangiocarcinoma in adults who have been previously treated.
  • Ivosidenib is indicated for people with acute myeloid leukemia and locally advanced or metastatic cholangiocarcinoma.
  • Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) in combination azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction .[rx] Relapsed or refractory AML in adults.[rx]
  • Acute Myeloid Leukemia
  • Locally Advanced Cholangiocarcinoma
  • Metastatic Cholangiocarcinoma
  • Refractory Acute Myeloid Leukemia (AML)
  • Relapsed Acute Myelogenous Leukemia (AML)

Use in Cancer

Ivosidenib is approved to treat adults whose cancer has a certain mutation in the IDH1 gene, including:

  • Acute myeloid leukemia (AML). It is used:
    • Alone or with azacitidine in patients with newly-diagnosed cancer who are aged 75 years and older or who, due to health problems, cannot receive intensive induction chemotherapy.
    • When cancer has come back or has not gotten better after previous treatment.
  • Cholangiocarcinoma ( cancer) has spread. It is used in adults whose cancer has been treated.

Ivosidenib is also being studied in the treatment of other types of cancer.

Contraindications

  • low amount of magnesium in the blood
  • low amount of calcium in the blood
  • low amount of potassium in the blood
  • Guillain-Barre
  • torsades de pointes, a type of abnormal heart rhythm
  • prolonged QT interval on EKG
  • abnormal EKG with QT changes from birth
  • pregnancy
  • a patient who is producing milk and breastfeeding

Strengths: 250 mg

Acute Myeloid Leukemia

  • 500 mg orally once daily until or unacceptable toxicity; for patients without disease or unacceptable toxicity, treat for a minimum of 6 months to allow time for response. Select patients for the treatment of AML based on the presence of IDH1 mutations in the blood or . Patients without IDH1 mutations at should be retested at because a mutation in IDH1 may emerge during therapy and at relapse.
  • For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Acute Myeloid Leukemia

75 years or older:

  • 500 mg orally once daily until disease progression or unacceptable toxicity; for patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
  • For the treatment of adult patients with newly-diagnosed AML with a susceptible IDH1 mutation as detected by an FDA-approved test who are 75 years older or who have comorbidities that preclude the use of intensive induction chemotherapy.

Dose Adjustments

  • (CrCl 60 to less than 90 mL/min) or moderate (CrCl 30 to less than 60 mL/min): No adjustment is recommended.
  • renal impairment (CrCl less than 30 mL/min): Data not available

Liver Dose Adjustments

  • Mild hepatic impairment (total less than or equal to the upper limit of normal [ULN] and aspartate aminotransferase [AST] greater than ULN or total bilirubin 1 to 1.5 x ULN and any AST): No adjustment recommended.
  • Moderate hepatic impairment (total bilirubin 1.5 to 3.0 x ULN and any value for AST), or severe hepatic impairment (total bilirubin greater than 3 x ULN and any value for AST): Data not available

Dose Adjustments

DIFFERENTIATION SYNDROME:

  • If differentiation syndrome is suspected, administer corticosteroids and initiate hemodynamic until symptom resolution and for a minimum of 3 days.
  • Interrupt therapy if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids. Resume therapy when signs and symptoms improve to Grade 2 or less.

NONINFECTIOUS (white blood cell [WBC] count greater than 25 x 10(9)/L or an absolute increase in total WBC of greater than 15 x 10(9)/L from ):

  • Initiate treatment with hydroxyurea, as per standard institutional practices, and leukapheresis if clinically indicated.
  • Taper hydroxyurea only after leukocytosis improves or resolves.
  • Interrupt therapy if leukocytosis is not improved with hydroxyurea, and then resume therapy at 500 mg daily when leukocytosis has resolved.

QTC INTERVAL GREATER THAN 480 MSEC TO 500 MSEC:

  • Monitor and supplement electrolyte levels as clinically indicated.
  • Review and adjust concomitant medications with known QTc interval-prolonging effects.
  • Interrupt therapy.
  • Restart therapy at 500 mg once daily after the QTc interval returns to less or equal to 480 msec.
  • Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation.

QTC INTERVAL GREATER THAN 500 MSEC:

  • Monitor and supplement electrolyte levels as clinically indicated.
  • Review and adjust concomitant medications with known QTc interval-prolonging effects.
  • Interrupt therapy.
  • Resume therapy at a reduced dose of 250 mg once daily when the QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec.
  • Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation.
  • Consider re-escalating the dose to 500 mg daily if an alternative etiology for QTc prolongation can be identified.

QTC INTERVAL PROLONGATION WITH SIGNS/SYMPTOMS OF LIFE-THREATENING ARRHYTHMIA:

  • Discontinue therapy permanently.

GUILLAIN-BARRE SYNDROME:

  • Discontinue therapy permanently.

OTHER GRADE 3 OR HIGHER TOXICITY CONSIDERED TO BE RELATED TO TREATMENT:

  • Interrupt therapy until toxicity resolves to Grade 2 or lower.
  • Resume therapy at 250 mg once daily; may increase to 500 mg once daily if toxicities resolve to Grade 1 or lower.
  • If Grade 3 or higher toxicity recurs, discontinue therapy.

DOSE MODIFICATION FOR USE WITH STRONG CYP450 3A4 INHIBITORS

  • If a strong CYP450 3A4 inhibitor must be coadministered, reduce the dose of this drug to 250 mg once daily.
  • If the strong CYP450 3A4 inhibitor is discontinued, increase the dose of this drug (after at least 5 half-lives of the strong CYP450 3A4 inhibitor) to the recommended dose of 500 mg once daily.

Administration advice:

  • This drug may be taken with or without food; however, it should not be administered with a high-fat meal because of an increase in drug concentration.
  • Do not split or crush tablets.
  • Administer this drug at about the same time each day.
  • If a dose is vomited, do not administer a replacement dose; wait until the next scheduled dose is due.
  • If a dose is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours.
  • Assess blood counts and blood chemistries prior to the initiation of therapy, at least once weekly for the first month, once every other week for the second month, and once monthly for the duration of therapy.
  • Monitor blood creatine phosphokinase weekly for the first month of therapy.
  • Monitor electrocardiograms (ECGs) at least once weekly for the first 3 weeks of therapy and then at least once monthly for the duration of therapy. Manage any abnormalities promptly.

Side Effects

The Most Common

  • headache
  • fatigue
  • joint or muscle pain
  • diarrhea
  • constipation
  • vomiting
  • nausea
  • decreased appetite
  • mouth pain and ulcers
  • stomach pain
  • difficulty falling asleep or staying asleep
  • dizziness, lightheadedness, or fainting
  • weakness or tingling sensation in legs, arms, or upper body; numbness and pain on one side or both sides of the body; changes in your ability to see, touch, hear, or taste; burning or prickling sensation; or difficulty breathing
  • chest pain

More common

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • blurred vision
  • burning, tingling, numbness or pain in the hands, arms, feet, or legs
  • chest pain or tightness
  • chills
  • confusion
  • cough
  • decreased urination
  • difficult or labored breathing
  • difficulty in moving
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • eye pain
  • fainting
  • fever
  • general feeling of illness
  • headache
  • irregular heartbeat, recurrent
  • joint pain, stiffness, or swelling
  • lower back, side, or stomach pain
  • muscle ache, cramps, pain, or stiffness
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • rapid weight gain
  • rash
  • the sensation of pins and needles
  • sore throat
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • stabbing pain
  • swelling of your arms, feet, or lower legs
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Rare

  • Inability to move the arms and legs
  • sudden numbness and weakness in the arms and legs
  • Cracked lips
  • decreased appetite
  • diarrhea
  • difficulty in swallowing
  • nausea
  • vomiting
  • decreased urination;
  • rapid weight gain; or
  • swelling in your arms or legs.
  • fast or pounding heartbeats, fluttering in your chest, shortness of breath, sudden dizziness (like you might pass out);
  • jaundice (yellowing of the skin or eyes);
  • fluid build-up around the stomach–rapid weight gain, stomach pain and bloating, trouble breathing while lying down;
  • low red blood cells (anemia)–pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet;
  • high white blood cell counts–fever, weakness, not feeling well, bleeding or bruising, nausea, loss of appetite, weight loss; or
  • nervous system problems–numbness, pain, tingling, weakness, burning or prickly feeling, vision or hearing problems, trouble breathing.

Drug Interactions

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on animal embryo-fetal toxicity studies, TIBSOVO may cause fetal harm when administered to a pregnant woman. There are no available data on TIBSOVO use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal
embryo-fetal toxicity studies, oral administration of ivosidenib to pregnant rats and rabbits during organogenesis was associated with embryo-fetal mortality and alterations to growth starting at 2 times the steady-state clinical exposure based on the AUC at the recommended
human dose (see Data). If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus.

Lactation

There are no data on the presence of ivosidenib or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment with TIBSOVO and for at least 1 month after the last dose.

Why is this medication prescribed?

Ivosidenib is used to treat a certain type of acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells) that has returned or that has not improved after previous treatment(s). Ivosidenib is also used alone or in combination with azacitidine (Onureg) to treat a certain type of AML in some adults older than 75 years of age as a first treatment. Ivosidenib is also used in adults who have already received previous treatment(s) to treat a certain type of cholangiocarcinoma (bile duct cancer) that has spread to nearby tissues or other parts of the body. Ivosidenib is in a class of medications called IDH1 inhibitors. It works by slowing or stopping the growth of cancer cells.

How should this medicine be used?

Ivosidenib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Do not take it with high-fat food such as eggs, butter, whole-milk dairy products (such as whole milk, cheese, and yogurt), fried foods, or fast food. Take ivosidenib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ivosidenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them. If you vomit after taking ivosidenib, do not take another dose. Continue your regular dosing schedule.

Your doctor may reduce your dose or temporarily or permanently stop your treatment with ivosidenib depending on your response to treatment or any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking ivosidenib,

  • tell your doctor and pharmacist if you are allergic to ivosidenib, any other medications, or any of the ingredients in ivosidenib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you or anyone in your family has or has ever had a prolonged QT interval (a condition that increases the risk of developing an irregular heartbeat that may cause fainting or sudden death); if you have or have ever had a slow or irregular heartbeat, heart failure, or other heart problems; low blood levels of sodium, potassium, calcium, or magnesium; nervous system problems; liver disease, including cirrhosis; or if you are receiving dialysis treatments or if you have or ever had kidney disease.
  • tell your doctor if you are pregnant or plan to become pregnant, or are breastfeeding. You should know that ivosidenib may decrease the effectiveness of hormonal contraceptives (birth control pills, patches, rings, or injections) while you are taking this medication. Talk to your doctor about using another form of birth control. If you become pregnant while taking ivosidenib, call your doctor immediately. Ivosidenib may cause fetal harm.
  • tell your doctor if are breastfeeding. Do not breastfeed during your treatment with ivosidenib and for 1 month after your final dose.

What special dietary instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet. Make sure you drink plenty of water or other fluids every day while you are taking ivosidenib.

What should I do if I forget a dose?

If your next dose is due in 12 hours or more, take the missed dose as soon as you remember it. However, if the next dose will be taken in less than 12 hours, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf
  5. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211192Orig1s009ltr.pdf
  6. https://pubchem.ncbi.nlm.nih.gov/compound/71657455
  7. https://go.drugbank.com/drugs/DB14568
  8. https://en.wikipedia.org/wiki/Ivosidenib
  9. https://www.drugs.com/mtm/ivosidenib.html
  10. https://medlineplus.gov/druginfo/meds/a618042.html
  11. https://www.cancer.gov/about-cancer/treatment/drugs/ivosidenib
  12. https://www.mayoclinic.org/drugs-supplements/ivosidenib-oral-route/side-effects/drg-20443890?p=1
  13. https://www.webmd.com/drugs/2/drug-175695/ivosidenib-oral/details/list-contraindications
  14. CAS Common Chemistry
    https://creativecommons.org/licenses/by-nc/4.0/
    https://commonchemistry.cas.org/detail?cas_rn=1448347-49-6
  15. ChemIDplus
    https://www.nlm.nih.gov/copyright.html
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=1448347496
    https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
  16. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    https://www.drugbank.ca/drugs/DB14568
  17. EPA DSSTox
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    https://comptox.epa.gov/dashboard/DTXSID801027928
    https://comptox.epa.gov/dashboard/chemical-lists/
  18. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/249162
  19. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/Q2PCN8MAM6
  20. ChEBI
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:145430
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  21. LiverTox
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Ivosidenib/
  22. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C114383
    https://ncit.nci.nih.gov
  23. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989958/
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  24. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    https://www.dgidb.org/drugs/IVOSIDENIB
  25. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9217
    https://www.guidetopharmacology.org/targets.jsp
  26. Therapeutic Target Database (TTD)
    http://idrblab.net/ttd/data/drug/details/D07DCG
  27. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  28. DailyMed
    https://www.nlm.nih.gov/copyright.html
    https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=IVOSIDENIB
  29. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002247-pip02-17
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002247-pip03-17
  30. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  31. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  32. FDA Medication Guides
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page
  33. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  34. NCI Cancer Drugs
    https://www.cancer.gov/policies/copyright-reuse
    https://www.cancer.gov/about-cancer/treatment/drugs/ivosidenib
  35. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    https://rxnav.nlm.nih.gov/id/rxnorm/2049873
  36. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=41061193-220086950
  37. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=41061193-220081096
  38. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    https://www.whocc.no/atc_ddd_index/
  39. Wikidata
    https://creativecommons.org/publicdomain/zero/1.0/
    https://www.wikidata.org/wiki/Q27895417
  40. https://pubchem.ncbi.nlm.nih.gov
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  41. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/mesh/2026879
    http://www.nlm.nih.gov/mesh/meshhome.html
    https://www.ncbi.nlm.nih.gov/mesh/68000970
    https://www.ncbi.nlm.nih.gov/mesh/68004791
  42. KEGG
    https://www.kegg.jp/kegg/legal.html
    http://www.genome.jp/kegg-bin/get_htext?br08302.keg
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
  43. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  44. PATENTSCOPE (WIPO)
    https://pubchem.ncbi.nlm.nih.gov/substance/393443997

More from this topic
  1. Vasodilator Drugs

    Reading text sizeA−AA+ Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Reading text sizeA−AA+ Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Reading text sizeA−AA+ Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    Reading text sizeA−AA+ DefinitionCholecalciferol is a steroid hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    Reading text sizeA−AA+ DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Reading text sizeA−AA+ Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    Reading text sizeA−AA+ DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid hormone. It is used in the treatment of hyperthyroidism. Methylthiouracil is an organosulfur compound that...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    Reading text sizeA−AA+ DefinitionPropylthiouracil is a Thyroid Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    Reading text sizeA−AA+ DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    Reading text sizeA−AA+ DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Ivosidenib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.